Philip Pizzo - Global Blood Director
| GBTDelisted Stock | USD 68.49 0.00 0.00% |
Director
Dr. Philip A. Pizzo, M.D. is an Independent Director of the Company. Dr. Pizzo currently serves as the David and Susan Heckerman Professor of Pediatrics and of Microbiology and Immunology at Stanford School of Medicine and is a founding director of the Stanford Distinguished Careers Institute. He previously served as Dean of the Stanford School of Medicine from 2001 to 2012, where he was also the Carl and Elizabeth Naumann Professor of Pediatrics and of Microbiology and Immunology. Before joining Stanford, he was the physicianinchief of Childrens Hospital in Boston and chair of the Department of Pediatrics at Harvard Medical School from 1996 to 2001. Prior to that, Dr. Pizzo was at the National Cancer Institute, eventually serving as chief of pediatrics and acting scientific director in the Division of Clinical Sciences. Dr. Pizzo is the author of more than 630 scientific articles and 16 books and monographs, has received numerous awards and honors, is a member of the National Academy of Medicine, and serves on several international boards. Dr. Pizzo holds a B.A. from Fordham University and an M.D. from the University of Rochester, School of Medicine. Dr. Pizzos qualifications to serve on our Board of Directors include his leadership in academic medicine, and his work in the fields of pediatric medicine, science, education and healthcare. since 2015.
| Age | 73 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 650 741-7700 |
| Web | www.globalbloodtx.com |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Kenneth Bronfin | Hasbro Inc | 58 | |
| Andy Martin | Hasbro Inc | 56 | |
| James Stewart | Rocky Brands | 80 | |
| Pierre Pichette | BRP Inc | 62 | |
| Mary Rainey | Hasbro Inc | 61 | |
| Harley Rouda | Rocky Brands | 53 | |
| Michael Hanley | BRP Inc | 52 | |
| Torsten Kreindl | Hasbro Inc | 53 | |
| Daniel ONeill | BRP Inc | 65 | |
| Michael Burns | Hasbro Inc | 59 | |
| William Cary | BRP Inc | 58 | |
| Hope Cochran | Hasbro Inc | 46 | |
| JeanGuy Martin | Academy Sports OutdoorsInc | N/A | |
| Loudon Owen | Academy Sports OutdoorsInc | N/A | |
| Richard Stoddart | Hasbro Inc | 55 | |
| William Jordan | Rocky Brands | 45 | |
| Joshua Bekenstein | BRP Inc | 59 | |
| Alistair Cox | Hasbro Inc | 55 | |
| Alan Hassenfeld | Hasbro Inc | 69 | |
| Peter Williams | Hasbro Inc | 63 | |
| Glenn Corlett | Rocky Brands | 73 | |
Management Performance
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
| Michael Bonney, Director | ||
| Stephanie Yao, IR Contact Officer | ||
| Myesha Lacy, IR Contact Officer | ||
| Mark Perry, Independent Director | ||
| Jeffrey Farrow, CFO | ||
| Myesha Edwards, IR Contact Officer | ||
| Philip Pizzo, Director | ||
| Glenn Pierce, Director | ||
| Willie Brown, Independent Director | ||
| Wendy Yarno, Director | ||
| Kevin Starr, Director | ||
| Hing Sham, Senior Vice President - Chemistry | ||
| Scott Morrison, Director | ||
| Deval Patrick, Independent Director | ||
| Tricia Suvari, Chief Legal Officer | ||
| Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
| David Johnson, Chief Commercial Officer | ||
| Charles Homcy, Director | ||
| Dawn Svoronos, Director | ||
| Ted Love, President CEO, Director | ||
| Eleanor Ramos, Chief Medical Officer | ||
| John Schembri, Vice President of Finance and Administration | ||
| Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -124.53 | |||
| Return On Asset | -23.82 | |||
| Profit Margin | (146.82) % | |||
| Operating Margin | (137.33) % | |||
| Current Valuation | 2.24 B | |||
| Shares Outstanding | 64.45 M | |||
| Shares Owned By Insiders | 2.72 % | |||
| Shares Owned By Institutions | 97.28 % | |||
| Number Of Shares Shorted | 9.23 M | |||
| Price To Earning | (13.97) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Global Blood in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Global Blood's short interest history, or implied volatility extrapolated from Global Blood options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Correlations Find global opportunities by holding instruments from different markets |